Epitope-based DNA vaccine for Alzheimer's disease: Translational study in macaques

Alzheimer's and Dementia

Volumn 10, Issue 3, 2014, Pages 284-295

  Evans, Claire F ^a   Davtyan, Hayk ^b,c   Petrushina, Irina ^c   Hovakimyan, Armine ^b   Davtyan, Arpine ^b   Hannaman, Drew ^a   Cribbs, David H ^c   Agadjanyan, Michael G ^b,c   Ghochikyan, Anahit ^b  

^a Ichor Medical Systems Inc   (United States)

^b INSTITUTE FOR MOLECULAR MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer's disease; Amyloid beta; Antibody response; Cellular immune response; DNA vaccine; Electroporation; Epitope vaccine; Rhesus macaques; Translational

Indexed keywords

AMYLOID BETA PROTEIN; AV 1955; DNA VACCINE; EPITOPE; UNCLASSIFIED DRUG; ALZHEIMER DISEASE VACCINE; ANTIBODY; IMMUNOGLOBULIN G;

ADULT; ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DNA IMMUNIZATION; DRUG POTENCY; ELECTROPORATION DEVICE; HELPER CELL; HUMORAL IMMUNITY; IMMUNOGENICITY; IN VITRO STUDY; MALE; MEDICAL DEVICE; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; TRANSLATIONAL RESEARCH; AMYLOID PLAQUE; ANIMAL; BLOOD; DOSE RESPONSE; HUMAN; IMMUNOLOGY; LONGITUDINAL STUDY; LYMPHOCYTE ACTIVATION; PHYSIOLOGY; RANDOMIZATION; TIME; TUMOR CELL LINE;

ALZHEIMER DISEASE; ALZHEIMER VACCINES; AMYLOID BETA-PEPTIDES; ANIMALS; ANTIBODIES; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; EPITOPES, T-LYMPHOCYTE; HUMANS; IMMUNOGLOBULIN G; LONGITUDINAL STUDIES; LYMPHOCYTE ACTIVATION; MACACA MULATTA; MALE; PLAQUE, AMYLOID; RANDOM ALLOCATION; T-LYMPHOCYTES, HELPER-INDUCER; TIME FACTORS; TRANSLATIONAL MEDICAL RESEARCH; VACCINES, DNA;

EID: 84899623721     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2013.04.505     Document Type: Article

References (51)

1. Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992;256:184-5.
2. Cerpa W, Dinamarca MC, Inestrosa NC. Structure-function implications in Alzheimer's disease: effect of Abeta oligomers at central synapses. Curr Alzheimer Res 2008;5:233-43.
3. Tanzi RE. The genetics of Alzheimer disease. Cold Spring Harb Perspect Med 2012;2:a006296.
4. Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ, et al. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci 2005;8:79-84.
5. Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 2007;8:101-12.
6. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, et al. Immunization with amyloid-beta attenuates Alzheimer disease-like pathology in the PDAPP mouse. Nature 1999;400:173-7.
7. Morgan D. Immunotherapy for Alzheimer's disease. J Intern Med 2011;269:54-63.
8. Lobello K, Ryan JM, Liu E, Rippon G, Black R. Targeting beta amyloid: a clinical review of immunotherapeutic approaches in Alzheimer's disease. Int J Alzheimers Dis 2012;2012:628070.
9. Ghochikyan A. Rationale for peptide and DNA based epitope vaccines for Alzheimer's disease immunotherapy. CNS Neurol Disord Drug Targets 2009;8:128-43.
10. Spires-Jones TL, Mielke ML, Rozkalne A, Meyer-Luehmann M, de Calignon A, Bacskai BJ, et al. Passive immunotherapy rapidly increases structural plasticity in a mouse model of Alzheimer disease. Neurobiol Dis 2009;33:213-20.
11. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000;6:916-9.
12. Kotilinek LA, Bacskai B,Westerman M, Kawarabayashi T, Younkin L, Hyman BT, et al. Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J Neurosci 2002;22:6331-5.
13. Agadjanyan MG, Ghochikyan A, Petrushina I, Vasilevko V, Movsesyan N, Mkrtichyan M, et al. Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from betaamyloid and promiscuous T cell epitope pan HLA DR-binding peptide. J Immunol 2005;174:1580-6.
14. Mamikonyan G, Necula M, Mkrtichyan M, Ghochikyan A, Petrushina I, Movsesyan N, et al. Anti-Abeta 1-11 antibody binds to different beta-amyloid species, inhibits fibril formation, and disaggregates preformed fibrils, but not the most toxic oligomers. J Biol Chem 2007;282:22376-86.
15. Petrushina I, Ghochikyan A, Mktrichyan M, Mamikonyan G, Movsesyan N, Davtyan H, et al. Alzheimer's disease peptide epitope vaccine reduces insoluble but not soluble/oligomeric Ab species in amyloid precursor protein transgenic mice. J Neurosci 2007; 27:12721-31.
16. Movsesyan N, Ghochikyan A, Mkrtichyan M, Petrushina I, Davtyan H, Olkhanud PB, et al. Reducing AD-like pathology in 3xTg-AD mouse model byDNA epitope vaccine: a novel immunotherapeutic strategy. PLoS ONE 2008;3:e21-4.
17. Davtyan H, Ghochikyan A, Movsesyan N, Ellefsen B, Petrushina I, Cribbs DH, et al. Delivery of a DNA vaccine for Alzheimer's disease by electroporation versus gene gun generates potent and similar immune responses. Neurodegener Dis 2012;10:261-4.
18. van Drunen Littel-van den Hurk S, Hannaman D. Electroporation for DNA immunization: clinical application. Expert Rev Vaccines 2010; 9:503-17.
19. Evans CF, Hannaman D. Current status of electroporation technologies for vaccine delivery. In: Singh M, editor. Novel immune potentiators and delivery technologies for next generation vaccines. New York: Springer; 2013. p. 185-215.
20. Movsesyan N, Mkrtichyan M, Petrushina I, Ross TM, Cribbs DH, Agadjanyan MG, et al. DNA epitope vaccine containing complement component C3d enhances anti-amyloid-beta antibody production and polarizes the immune response towards a Th2 phenotype. J Neuroimmunol 2008;205:57-63.
21. Baraldo K, Mori E, Bartoloni A, Petracca R, Giannozzi A, Norelli F, et al. N19 polyepitope as a carrier for enhanced immunogenicity and protective efficacy of meningococcal conjugate vaccines. Infect Immunol 2004;72:4884-7.
22. James EA, Bui J, Berger D, Huston L, Roti M, Kwok WW. Tetramerguided epitope mapping reveals broad, individualized repertoires of tetanus toxin-specific CD41 T cells and suggests HLA-based differences in epitope recognition. Int Immunol 2007;19:1291-301.
23. Lee M, Bard F, Johnson-Wood K, Lee C, Hu K, Griffith SG, et al. Abeta42 immunization in Alzheimer's disease generates Abeta N-terminal antibodies. Ann Neurol 2005;58:430-5.
24. Davtyan H, Mkrtichyan M, Movsesyan N, Petrushina I, Mamikonyan G, Cribbs DH, et al. DNA prime-protein boost increased the titer, avidity and persistence of anti-Abeta antibodies in wild-type mice. Gene Ther 2010;17:261-71.
25. Kayed R, Head E, Sarsoza F, Saing T, Cotman CW, Necula M, et al. Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol Neurodegener 2007;2:18.
26. Davtyan H, Ghochikyan A, Cadagan R, Zamarin D, Petrushina I, Movsesyan N, et al. The immunological potency and therapeutic potential of a prototype dual vaccine against influenza and Alzheimer's disease. J Transl Med 2011;9:127.
27. Ulmer JB, Wahren B, Liu MA. DNA vaccines: recent technological and clinical advances. Discov Med 2006;6:109-12.
28. Vasan S, Hurley A, Schlesinger SJ, Hannaman D, Gardiner DF, Dugin DP, et al. In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers. PLoS One 2011;6:e19252.
29. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A 1998;95:6448-53.
30. Eli Lilly and Company announces top-line results on solanezumab phase 3 clinical trials in patients with Alzheimer's disease, August 24, 2012. Available at: http://newsroom.lilly.com/releasedetail.cfm? releaseid5702211. Accessed May 31, 2013
31. Johnson & Johnson announces discontinuation of phase 3 development of bapineuzumab intravenous (IV) in mild-to-moderate Alzheimer's disease, August 6, 2012. Available at: http://www.jnj.com/ connect/news/all/johnson-and-johnson- announces-discontinuationof- phase-3-development-of-bapineuzumab-intravenous-iv- in-mild-tomoderate- alzheimers-disease. Accessed May 31, 2013.
32. Sperling R, Salloway S, Raskind MA, Ferris S, Liu E, Yuen E, et al. A randomized double-blind, placebo-controlled clinical trial of intravenous bapineuzumab in patients with Alzheimer's disease who are apolipoprotein E ?4 carriers. Presented at the 16th Congress of the European Federation of Neurological Societies; September 8-11, 2012; Stockholm, Sweden.
33. Salloway S, Sperling R, Honig L, Porsteinsson A, Sabbagh M, Liu E, et al. A randomized double-blind, placebo-controlled clinical trial of intravenous bapineuzumab in patients with Alzheimer's disease who are apolipoprotein E ?4 non-carriers. Presented at the 16th Congress of the European Federation of Neurological Societies; September 8- 11, 2012; Stockholm, Sweden.
34. Cribbs DH. Abeta DNA vaccination for Alzheimer's disease: focus on disease prevention. CNS Neurol Disord Drug Targets 2010; 9:207-16.
35. Olkhanud PB, Mughal M, Ayukawa K, Malchinkhuu E, Bodogai M, Feldman N, et al. DNA immunization with HBsAg-based particles expressing a B cell epitope of amyloid beta-peptide attenuates disease progression and prolongs survival in a mouse model of Alzheimer's disease. Vaccine 2012;30:1650-8.
36. Kim HD, Jin JJ, Maxwell JA, Fukuchi K. Enhancing Th2 immune responses against amyloid protein by a DNA prime-adenovirus boost regimen for Alzheimer's disease. Immunol Lett 2007;112:30-8.
37. Wang CY, Finstad CL, Walfield AM, Sia C, Sokoll KK, Chang TY, et al. Site-specific UBITh amyloid-beta vaccine for immunotherapy of Alzheimer's disease. Vaccine 2007;25:3041-52.
38. Wiessner C, Wiederhold KH, Tissot AC, Frey P, Danner S, Jacobson LH, et al. The second-generation active Abeta immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects. J Neurosci 2011; 31:9323-31.
39. Winblad B, Andreasen N, Minthon L, Floesser A, Imbert G, Dumortier T, et al. Safety, tolerability, and antibody response of active Abeta immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study. Lancet Neurol 2012;11:597-604.
40. Tabira T. Immunization therapy for Alzheimer disease: a comprehensive review of active immunization strategies. Tohoku J Exp Med 2010;220:95-106.
41. Lemere CA, Masliah E. Can Alzheimer disease be prevented by amyloid-beta immunotherapy? Nat Rev Neurol 2010;6:108-19.
42. Delrieu J, Ousset PJ, Caillaud C, Vellas B. "Clinical trials in Alzheimer's disease": immunotherapy approaches. J Neurochem 2012; 120:186-93.
43. Schneeberger A, Mandler M, Mattner F, Schmidt W. AFFITOME technology in neurodegenerative diseases: the doubling advantage. Hum Vaccin 2010;6:948-52.
44. Gandy S, DeMattos RB, Lemere CA, Heppner FL, Leverone J, Aguzzi A, et al. Alzheimer A beta vaccination of rhesus monkeys (Macaca mulatta). Alzheimer Dis Assoc Disord 2004;18:44-6.
45. Lemere CA, Beierschmitt A, Iglesias M, Spooner ET, Bloom JK, Leverone JF, et al. Alzheimer's disease Abeta vaccine reduces central nervous system Abeta levels in a non-human primate, the Caribbean vervet. Am J Pathol 2004;165:283-97.
46. Qu BX, Xiang Q, Li L, Johnston SA, Hynan LS, Rosenberg RN. Abeta42 gene vaccine prevents Abeta42 deposition in brain of double transgenic mice. J Neurol Sci 2007;260:204-13.
47. Tokita Y, Kaji K, Lu J, Okura Y, Kohyama K, Matsumoto Y. Assessment of non-viral amyloid-beta DNA vaccines on amyloid-beta reduction and safety in rhesus monkeys. J Alzheimers Dis 2010; 22:1351-61.
48. Li S,Wang H, Lin X, Xu J, Xie Y, Yuan Q, et al. Specific humoral immune responses in rhesus monkeys vaccinated with the Alzheimer's disease-associated beta-amyloid 1-15 peptide vaccine. Chinese Med J 2005;118:660-4.
49. Sardesai NY, Weiner DB. Electroporation delivery of DNA vaccines: prospects for success. Curr Opin Immunol 2011;23:421-9.
50. Davtyan H, Ghochikyan A, Petrushina I, Hovakimyan A, Davtyan A, Poghosyan A, et al. Immunogenicity, efficacy, safety, and mechanism of action of epitope vaccine (Lu AF20513) for Alzheimer's disease: prelude to a clinical trial. J Neurosci 2013;33:4923-34.
51. Klunk WE. Amyloid imaging as a biomarker for cerebral betaamyloidosis and risk prediction for Alzheimer dementia. Neurobiol Aging 2011;32:S20-36.